Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association

Ji Guang Wang, Kazuomi Kario, Titus Lau, Yong Quek Wei, Chang Gyu Park, Cheol Ho Kim, Jun Huang, Weizhong Zhang, Yong Li, Peter Yan, Dayi Hu

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease.

Original languageEnglish
Pages (from-to)423-430
Number of pages8
JournalHypertension Research
Volume34
Issue number4
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

Calcium Channel Blockers
Hypertension
Antihypertensive Agents
Blood Pressure
Stroke
Amlodipine
North America
Coronary Disease
1,4-dihydropyridine
Randomized Controlled Trials
Myocardial Infarction
Placebos
Pharmaceutical Preparations

Keywords

  • ambulatory blood pressure
  • calcium channel blockers
  • cardiovascular endpoints
  • randomized controlled trials
  • target organ damage

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians : A scientific statement from the Asian Pacific Heart Association. / Wang, Ji Guang; Kario, Kazuomi; Lau, Titus; Wei, Yong Quek; Park, Chang Gyu; Kim, Cheol Ho; Huang, Jun; Zhang, Weizhong; Li, Yong; Yan, Peter; Hu, Dayi.

In: Hypertension Research, Vol. 34, No. 4, 01.04.2011, p. 423-430.

Research output: Contribution to journalReview article

Wang, Ji Guang ; Kario, Kazuomi ; Lau, Titus ; Wei, Yong Quek ; Park, Chang Gyu ; Kim, Cheol Ho ; Huang, Jun ; Zhang, Weizhong ; Li, Yong ; Yan, Peter ; Hu, Dayi. / Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians : A scientific statement from the Asian Pacific Heart Association. In: Hypertension Research. 2011 ; Vol. 34, No. 4. pp. 423-430.
@article{bf780eaa01f442e895d33849db543fcb,
title = "Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association",
abstract = "Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease.",
keywords = "ambulatory blood pressure, calcium channel blockers, cardiovascular endpoints, randomized controlled trials, target organ damage",
author = "Wang, {Ji Guang} and Kazuomi Kario and Titus Lau and Wei, {Yong Quek} and Park, {Chang Gyu} and Kim, {Cheol Ho} and Jun Huang and Weizhong Zhang and Yong Li and Peter Yan and Dayi Hu",
year = "2011",
month = "4",
day = "1",
doi = "10.1038/hr.2010.259",
language = "English",
volume = "34",
pages = "423--430",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians

T2 - A scientific statement from the Asian Pacific Heart Association

AU - Wang, Ji Guang

AU - Kario, Kazuomi

AU - Lau, Titus

AU - Wei, Yong Quek

AU - Park, Chang Gyu

AU - Kim, Cheol Ho

AU - Huang, Jun

AU - Zhang, Weizhong

AU - Li, Yong

AU - Yan, Peter

AU - Hu, Dayi

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease.

AB - Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease.

KW - ambulatory blood pressure

KW - calcium channel blockers

KW - cardiovascular endpoints

KW - randomized controlled trials

KW - target organ damage

UR - http://www.scopus.com/inward/record.url?scp=79953698165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953698165&partnerID=8YFLogxK

U2 - 10.1038/hr.2010.259

DO - 10.1038/hr.2010.259

M3 - Review article

C2 - 21228778

AN - SCOPUS:79953698165

VL - 34

SP - 423

EP - 430

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 4

ER -